menu
    • menu
    [{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Emactuzumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"SynOx Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"SynOx Therapeutics \/ HealthCap","highestDevelopmentStatusID":"6","companyTruncated":"SynOx Therapeutics \/ HealthCap"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Emactuzumab","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SynOx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"SynOx Therapeutics \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Therapeutics \/ Forbion"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"SynOx Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Gilde Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SynOx Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SynOx Therapeutics \/ Gilde Healthcare","highestDevelopmentStatusID":"14","companyTruncated":"SynOx Therapeutics \/ Gilde Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals by SynOx Therapeutics

    Menu

    SynOx Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Gilde Healthcare

                            Deal Size : $92.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            SynOx Raises $92M in Series B, Doses Phase 3 Trial Patients

                            Details : The proceeds are supporting Phase 3 of RG-7155 (emactuzumab), a potentially best-in-class CSF-1 receptor inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.

                            Brand Name : RG-7155

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 30, 2024

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Gilde Healthcare

                            Deal Size : $92.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Hercules Capital

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            SynOx Secures $35M Debt Financing to Advance Emactuzumab Development and Commercialization

                            Details : The financing is intended to support the clinical development of Synox's late-stage product and the commercialization of emactuzumab for treating Tenosynovial Giant Cell Tumor.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Hercules Capital

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Forbion

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Donesta Safety Study for Menopause Completes Treatment Phase

                            Details : The proceeds will be used to advance late-stage product Emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Forbion

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Emactuzumab Designated as an Orphan Medicinal Product in Europe

                            Details : Emactuzumab is a novel monoclonal antibody inhibiting CSF-1R that offers a short course of treatment. Phase I/II studies indicated good tolerability and a manageable safety profile and substantial preliminary efficacy in TGCT patients.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 31, 2022

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SynOx Therapeutics

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Healthcaps India

                            Deal Size : $45.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            SynOx Therapeutics raises €37M in Series A Financing

                            Details : The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.

                            Brand Name : CXD301

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 19, 2020

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Healthcaps India

                            Deal Size : $45.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth